SLFN5 and glioblastoma: In GBM, SLFN5 impedes STAT1-mediated transcription of interferon-stimulated genes (ISGs) following type I IFN treatment, creating a negative feedback loop as SLFN5 is both itself an ISG and a negative regulator of IFN responses [18].